LMG Life Sciences Recognizes Hamilton Brook Smith Reynolds and Attorneys David Brook
November 7, 2017, Concord and Boston, MA – LMG Life Sciences identified Hamilton Brook Smith Reynolds as one of the leaders in Patent Strategy and Management among law firms in the U.S. and recognized Principals Dave Brook individually. The publication’s research for this ranking “is based on reviewing nearly 1,000 interviews and surveys completed by partners active in the market.” They also spoke to clients and leading lawyers to help inform their research process, in addition to reviewing public information.
John L. DuPré, President and Principal at Hamilton Brook Smith Reynolds, remarked, “Our firm has a long history of working with some of the world’s most innovative life science companies, and we are proud LMG Life Sciences has recognized our work and the contributions of Dave..”
Founding partner and Principal David Brook was recognized by LMG Life Sciences for prosecution and patent strategy and management in the areas of: antibiotics, antibodies, antiviral drugs, biologics, DNA sequencing, drug formation and in vitro diagnostics. Dave has more than forty years of experience counseling clients concerning patent strategies. Previously Dave served on the corporate patent staffs of Itek Corporation, the Atlantic Research Corporation and E.I. du Pont de Nemours and Company.
David E. Brook
Chairman Emeritus and Co-Founder, Retired